Discovery of selective, small-molecule inhibitors of RNA complexes - I. The Tat protein/TAR RNA complexes required for HIV-1 transcription

Bioorganic and Medicinal Chemistry

Volumn 5, Issue 6, 1997, Pages 1173-1184

  Mei, Houng Yau ^a   Mack, David P ^a   Galan, Adam A ^a   Halim, Nadia S ^a   Heldsinger, Andrea ^a   Loo, Joseph A ^a   Moreland, David W ^a   Sannes Lowery, Kristin A ^a   Sharmeen, Lamia ^a   Truong, Hoa N ^a   Czarnik, Anthony W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIVIRUS AGENT; CAMPTOTHECIN; GENTAMICIN; NEOMYCIN; REV PROTEIN; STREPTOMYCIN; TRANSACTIVATOR PROTEIN;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DRUG DESIGN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN RNA BINDING; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

AMINO ACID SEQUENCE; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE SEQUENCE; BENZODIAZEPINONES; CAMPTOTHECIN; GENE PRODUCTS, TAT; HELA CELLS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PYRROLES; RNA, VIRAL; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031005114     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(97)00064-3     Document Type: Conference Paper

References (51)

1. (a) Vaishnav, Y. N.; Wong-Staal, F. Annu. Rev. Biochem. 1991, 60, 577.
2. (b) Karn, J.; Graeble, M. A. Trends in Genet. 1992, 8, 365.
3. (c) Fisher, A. G.; Feinberg, M. B.; Josephs, S. F.; Harper, M. E.; Marselle, L. M.; Reyes, G.; Gonda, M. A., Aldovini, A.; Debouk, C.; Gallo, R. C.; Wong-Staal, F. Nature (London) 1986, 320, 367.
4. (a) Muesing, M. A.; Smith, D. H; Capon, D. J. Cell 1987, 48, 691.
5. (b) Feng, S.; Holland, E. C. Nature (London) 1988, 334, 165.
6. (c) Berkhout, B.; Silverman, R.; Jeang, K.-T. Cell 1989, 59, 273.
7. (a) Roy, S.; Delling, U.; Chen, C.-H.; Rosen, C. A.; Sonenberg, N. Genes Develop. 1990, 4, 1365.
8. (b) Dingwall, C.; Ernberg, I.; Gait, M. J.; Green, S. M.; Heaphy, S.; Karn, J.; Lowe, A. D.; Singh, M.; Skinner, M. A. EMBO J. 1990, 9, 4145.
9. (c) Delling, U.; Reid, L. S.; Barnett, R. W.; Ma, M. Y.-X.; Climie, S.; Sumner-Smith, M.; Sonenberg, N. J. Virol. 1992, 65, 7012.
10. Johnston, M. I.; Hoth, D. F. Science 1993, 260, 1286.
11. (a) Chodakewitz, J. A.; Emini, E. A. PCT Int. Appl. CODEN: PIXXD2. WO 9623509 A1 960808.
12. (b) Larder, B. A.; Kohli, A.; Bloor, S.; Kemp, S. D., Harrigan, P. R.; Schooley, R. T.; Lange, J. M. A.; Pennington, K. N.; St Clair, M. H. J. Virol. 1996, 70, 5922.
13. (c) Katlama, C.; Ingrand, D.; Loveday, C.; Clumeck, N.; Mallolas, J.; Staszewski, S.; Johnson, M.; Hill, A. M. J. Am. Med. Assoc. 1996, 276, 118.
14. (a) Sullenger, B. A.; Gallardo, H. F.; Ungers, G. E.; Gilboa, E. J. Virol. 1991, 65, 6811.
15. (b) Ecker, D. J.; Vickers, T. A.; Bruice, T. W.; Freier, S. M.; Jenison, R. D.; Manoharan, M.; Zounes, M. Science 1992, 257, 958.
16. (c) HIV Tat Inhibitor from Allelix Enters Phase I Trials. Antiviral Agents Bulletin 1993, 6, 291
17. Mei, H.-Y.; Galan, A. A.; Halim, N. S.; Mack, D. P.; Moreland, D. W.; Sanders, K. B.; Truong, H. N.; Czarnik, A. W. Bioorg. Med. Chem. Lett. 1995, 5, 2755.
18. (a) Hsu, M.-C.; Schutt, A. D.; Holly, M.; Slice, L. W.; Sherman, M. I.; Richman, D. D.; Potash, M. J.; Volsky, D. J. Science 1991, 254, 1799.
19. (b) Michne, W. F.; Schroeder, J. D.; Bailey, T. R. J. Med. Chem. 1993, 36, 2701.
20. Hsu, M.-C.; Cupelli, L. A. J. Virol. 1995, 69, 2640.
21. Young, D. C.; Kingsley, S. D.; Ryan, K. A.; Dutko, F. J. Anal. Biochem. 1993, 275, 24.
22. Sharp, P. A.; Marciniak, R. A. Cell 1989, 59, 229.
23. Tao, J.; Frankel, A. D. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 2723.
24. (a) Hauber, J.; Malim, M. I. I.; Cullen, B. R. J. Virol. 1989, 63, 1181.
25. (b) Calnan, B. J.; Tidor, B.; Biancalana, S.; Hudson, D.; Frankel, A. D. Science 1991, 252, 1167.
26. (a) Weeks, K. M.; Ampe, C.; Schultz, S. C.; Steitz, T. A.; Crothers, D. M. Science 1990, 249, 1281.
27. (b) Frankel, A. D. Protein Science 1992, 1, 1539.
28. (a) Puglisi, J. D.; Tan, R.; Calnan, B. J.; Frankel, A. D.; Williamson, J. R. Science 1992, 257, 76.
29. (b) Aboul-ela, F.; Karn, J.; Varani, G. J. Mol. Biol. 1995, 253, 313.
30. (c) Aboul-ela, F.; Karn, J.; Varani, G. Nucleic Acids Res. 1996, 24, 3974.
31. Long, K. S.; Crothers, D. M. Biochemistry 1995, 34, 8885.
32. Uderfriend, S.; Gerber, L.; Nelson, N. Anal. Biochem. 1987, 161, 494.
33. (a) Weeks, K. M.; Crothers, D. M. Biochem, 1992, 31, 10281.
34. (b) Calnan, B. J.; Biancalana, S.; Hudson, D.; Frankel, A. D. Genes Dev. 1991, 5, 201.
35. A dissociation constant was not determined due to the fact that the titration data did not show binding saturation at the concentrations studied. Since the concentrations examined should have been sufficient to reach saturation, this may indicate a difference between SPA and other techniques for observing the Tat-TAR interaction. A number of possibilities exist to explain this difference including that in the SPA technique the RNA is bound to a solid-phase particle and that the assay was optimized for signal-to-noise ratio. Either of these explanations would affect apparent values for the dissociation constant. Further work will be needed to understand the thermodynamic and kinetic aspects of this assay.
36. Churcher, M.; Lamont, C.; Dingwall, C.; Green, S. M.; Lowe, A. D.; Butler, P. J. G.; Gait, M. J.; Karn, J. J. Mol. Biol. 1993, 230, 90.
37. (a) Smith, R. D.; Loo, J. A.; Edmonds, C. G.; Barinaga, C. J.; Udseth, H. R. Anal. Chem. 1990, 62, 882.
38. (b) Ganem, B.; Henion, J. D. Chemtracts-Org. Chem. 1993, 6, 1.
39. (c) Siuzdak, G. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 11290.
40. (d) Loo, J. A. Bioconj. Chem. 1995, 6, 644.
41. Loo, J. A.; Sannes-Lowery, K. A.; Hu, P.; Mei, K-Y.; Mack, D. P. NATO ASI Series on New Methods for the Study of Molecular Aggregates; Standing, K. G., Ed.; Kluwer, in press.
42. Moazed, D.; Noller, H. F. Science 1987, 327, 389.
43. Du, B.; Wu, P.; Boldt-Houle, D. M.; Terwilliger, E. F. Gene Ther. 1996, 3, 254.
44. Li, C. J.; Wang, C.; Pardee, A. B. J. Biol. Chem. 1994, 269, 7051.
45. (a) Ensoli, B.; Gendelman, R.; Markham, P.; Fiorelli, V.; Colombini, S.; Raffeld, M.; Cafaro, A.; Chang, H.-K.; Brady, J. N.; Gallo, R. C. Nature (London) 1995, 371, 674.
46. (b) Milani, D.; Mazzoni, M.; Borgatti, P.; Zauli, G.; Cantley, L.; Capitani, S. J. Biol. Chem. 1996, 277, 22961.
47. (c) Sastry, K. J.; Marin, M. C.; Nehete, P. N.; McConnell, K.; El-Naggar, A. K.; McDonnell, T. J. Oncogene 1996, 13, 487.
48. (a) Stewart, J. M.; Young, J. D. In Solid Phase Peptide Synthesis, 2nd ed.; Pierce Chemical: Rockford, 1984.
49. (b) Bodansky, M.; Bodansky, A. In The Practice of Peptide Synthesis; Springer: Berlin, 1984.
50. Frankel, A. D.; Bredt, D. S.; Pabo, C. O. Science 1988, 240, 70.
51. Applied Biosystems User Bulletin No. 53. RNA Synthesis with DMT-cyanoethyl RNA Phosphoramidites.